T1d: #NephJC
Key requirements included:
❇️ biopsy-proven IgAN within 10 yrs
❇️ eGFR ≥30 mL/min/1.73 m²
❇️ persistent proteinuria ≥0.75 g/day
❇️ maximally tolerated RAS blockade for ≥12 weeks
❇️ SGLT2-inhibitor allowed
Key requirements included:
❇️ biopsy-proven IgAN within 10 yrs
❇️ eGFR ≥30 mL/min/1.73 m²
❇️ persistent proteinuria ≥0.75 g/day
❇️ maximally tolerated RAS blockade for ≥12 weeks
❇️ SGLT2-inhibitor allowed
November 19, 2025 at 2:23 AM
T1d: #NephJC
Key requirements included:
❇️ biopsy-proven IgAN within 10 yrs
❇️ eGFR ≥30 mL/min/1.73 m²
❇️ persistent proteinuria ≥0.75 g/day
❇️ maximally tolerated RAS blockade for ≥12 weeks
❇️ SGLT2-inhibitor allowed
Key requirements included:
❇️ biopsy-proven IgAN within 10 yrs
❇️ eGFR ≥30 mL/min/1.73 m²
❇️ persistent proteinuria ≥0.75 g/day
❇️ maximally tolerated RAS blockade for ≥12 weeks
❇️ SGLT2-inhibitor allowed
SGLT2-Inhibitoren, die ursprünglich als Blutzuckersenker zur Behandlung des #Typ-2-Diabetes entwickelt wurden, werden zunehmend auch bei Menschen mit chronischen Nierenerkrankungen eingesetzt.
SGLT2-Inhibitoren schützen Nieren auch bei Nichtdiabetikern und bei vorgeschädigten Nieren – Deutsches Ärzteblatt
www.aerzteblatt.de
November 14, 2025 at 7:02 PM
SGLT2-Inhibitoren, die ursprünglich als Blutzuckersenker zur Behandlung des #Typ-2-Diabetes entwickelt wurden, werden zunehmend auch bei Menschen mit chronischen Nierenerkrankungen eingesetzt.
We have a new therapy for type 1 diabetes! FINE-ONE with significant proteinuria reduction compared to placebo on a background of RASi with an acceptable safety profile. Where’s the simultaneous pub?? Sglt2 inhibitors are next…#kidneywk
November 6, 2025 at 3:26 PM
We have a new therapy for type 1 diabetes! FINE-ONE with significant proteinuria reduction compared to placebo on a background of RASi with an acceptable safety profile. Where’s the simultaneous pub?? Sglt2 inhibitors are next…#kidneywk
If my house is on fire, and my only option to put out the fire is to douse it in water, douse it in water. I dont like it but it’s the only disease modifying treatment available in many places (hopefully not for long). Also doesn’t need to be an “or”, I start the SGLT2 when I taper the pred. #NephJC
October 29, 2025 at 2:18 AM
If my house is on fire, and my only option to put out the fire is to douse it in water, douse it in water. I dont like it but it’s the only disease modifying treatment available in many places (hopefully not for long). Also doesn’t need to be an “or”, I start the SGLT2 when I taper the pred. #NephJC
#MedNews - SGLT2 inhibitor #empagliflozin significantly reduces the risk for acute and chronic kidney injury, regardless of the acute dip in eGFR soon after initiation and irrespective of the reason for treatment.
Full story 👉 buff.ly/YdMh728
#KidneyInjury #MedSky
Full story 👉 buff.ly/YdMh728
#KidneyInjury #MedSky
Empagliflozin offers significant renoprotection across multiple patient subgroups
SGLT2 inhibitor empagliflozin significantly reduces the risk for acute and chronic kidney injury, regardless of the acute dip in eGFR soon after initiation and irrespective of the reason for…
buff.ly
October 21, 2025 at 3:15 PM
#MedNews - SGLT2 inhibitor #empagliflozin significantly reduces the risk for acute and chronic kidney injury, regardless of the acute dip in eGFR soon after initiation and irrespective of the reason for treatment.
Full story 👉 buff.ly/YdMh728
#KidneyInjury #MedSky
Full story 👉 buff.ly/YdMh728
#KidneyInjury #MedSky
looking at my clinic schedule for tomorrow and making a mental note that just says “start this one on an SGLT2 inhibitor … start this one on an SGLT2 inhibitor … let’s go ahead and start this one on an SGLT2 inhibitor … SGLT2 inhibitor for this one too … hmm, let’s try an SGLT2 inhibitor …”
October 20, 2025 at 3:29 AM
looking at my clinic schedule for tomorrow and making a mental note that just says “start this one on an SGLT2 inhibitor … start this one on an SGLT2 inhibitor … let’s go ahead and start this one on an SGLT2 inhibitor … SGLT2 inhibitor for this one too … hmm, let’s try an SGLT2 inhibitor …”
These findings provide genetic support that SGLT2 inhibition increases osteoporosis risk despite raising BMD. Total testosterone does not appear to mediate this relationship, suggesting other pathways or direct skeletal effects drive the observed bone fragility.
SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study
Whether sodium–glucose cotransporter 2 (SGLT2) inhibitors elevate osteoporosis risk remains controversial, and the underlying metabolic pathways are u…
www.sciencedirect.com
October 19, 2025 at 10:22 AM
These findings provide genetic support that SGLT2 inhibition increases osteoporosis risk despite raising BMD. Total testosterone does not appear to mediate this relationship, suggesting other pathways or direct skeletal effects drive the observed bone fragility.
New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#OpenAccess
#MedSky #EndoSky #RenalSky
#SGLT2 inhibitor #CKD
#OpenAccess
#MedSky #EndoSky #RenalSky
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis
SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of
the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes
status, heart failure status,...
thelancet.com
October 10, 2025 at 10:38 PM
New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#OpenAccess
#MedSky #EndoSky #RenalSky
#SGLT2 inhibitor #CKD
#OpenAccess
#MedSky #EndoSky #RenalSky
The reno-protective effects of SGLT2 inhibitors cannot be fully explained by their glucose-lowering actions.
Quaggin & team now show SGLT2 inhibition increases tissue levels of SAM, resulting in enhanced H3K27 trimethylation & repression of inflammatory genes: www.jci.org/articles/vie...
Quaggin & team now show SGLT2 inhibition increases tissue levels of SAM, resulting in enhanced H3K27 trimethylation & repression of inflammatory genes: www.jci.org/articles/vie...
October 7, 2025 at 4:15 PM
The reno-protective effects of SGLT2 inhibitors cannot be fully explained by their glucose-lowering actions.
Quaggin & team now show SGLT2 inhibition increases tissue levels of SAM, resulting in enhanced H3K27 trimethylation & repression of inflammatory genes: www.jci.org/articles/vie...
Quaggin & team now show SGLT2 inhibition increases tissue levels of SAM, resulting in enhanced H3K27 trimethylation & repression of inflammatory genes: www.jci.org/articles/vie...
SGLT2 inhibitors in CKD: are they really effective in all patients?
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
October 7, 2025 at 1:15 PM
SGLT2 inhibitors in CKD: are they really effective in all patients?
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
もう既にいろいろとガタが来ているし、たとえば20歳代の機動力よ再び、なんてことはイチミリたりとも思ってないんだけど、「身から出た錆」の体調不良はちょっとずつましにしていこうと思いました。
糖尿病医の書いた『も○づきさん同人誌』たとえばSGLT2阻害薬の副作用やそれにともなう過食の可能性についても書かれてあって、糖尿病全般に広く浅く目配せがしてあってよい……
なにはともあれ痩せたい。
糖尿病医の書いた『も○づきさん同人誌』たとえばSGLT2阻害薬の副作用やそれにともなう過食の可能性についても書かれてあって、糖尿病全般に広く浅く目配せがしてあってよい……
なにはともあれ痩せたい。
October 5, 2025 at 2:18 AM
もう既にいろいろとガタが来ているし、たとえば20歳代の機動力よ再び、なんてことはイチミリたりとも思ってないんだけど、「身から出た錆」の体調不良はちょっとずつましにしていこうと思いました。
糖尿病医の書いた『も○づきさん同人誌』たとえばSGLT2阻害薬の副作用やそれにともなう過食の可能性についても書かれてあって、糖尿病全般に広く浅く目配せがしてあってよい……
なにはともあれ痩せたい。
糖尿病医の書いた『も○づきさん同人誌』たとえばSGLT2阻害薬の副作用やそれにともなう過食の可能性についても書かれてあって、糖尿病全般に広く浅く目配せがしてあってよい……
なにはともあれ痩せたい。
Besides SGLT2 inhibitors are there any other drug induced causes of DKA?
December 4, 2024 at 6:56 PM
Besides SGLT2 inhibitors are there any other drug induced causes of DKA?
RCT of dapagliflozin versus placebo.
Designed as crossover study. Looking at albuminuria.
Interestingly there were increases in the PO4, PTH, FGF23.
Thought to be due to increased absorption of PO4 by blocking SGLT2.
https://cjasn.asnjournals.org/content/14/1/66
#KidneyWk
Designed as crossover study. Looking at albuminuria.
Interestingly there were increases in the PO4, PTH, FGF23.
Thought to be due to increased absorption of PO4 by blocking SGLT2.
https://cjasn.asnjournals.org/content/14/1/66
#KidneyWk
November 22, 2024 at 10:38 PM
RCT of dapagliflozin versus placebo.
Designed as crossover study. Looking at albuminuria.
Interestingly there were increases in the PO4, PTH, FGF23.
Thought to be due to increased absorption of PO4 by blocking SGLT2.
https://cjasn.asnjournals.org/content/14/1/66
#KidneyWk
Designed as crossover study. Looking at albuminuria.
Interestingly there were increases in the PO4, PTH, FGF23.
Thought to be due to increased absorption of PO4 by blocking SGLT2.
https://cjasn.asnjournals.org/content/14/1/66
#KidneyWk
Crucial role for Sodium Hydrogen Exchangers in SGLT2 inhibitor-induced arterial relaxations https://www.biorxiv.org/content/10.1101/2023.12.05.570303v1
Crucial role for Sodium Hydrogen Exchangers in SGLT2 inhibitor-induced arterial relaxations https://www.biorxiv.org/content/10.1101/2023.12.05.570303v1
Introduction: Sodium dependent glucose transporter 2 (SGLT2 or SLC5A2) inhibitors effectively lower
www.biorxiv.org
December 8, 2023 at 5:05 PM
Crucial role for Sodium Hydrogen Exchangers in SGLT2 inhibitor-induced arterial relaxations https://www.biorxiv.org/content/10.1101/2023.12.05.570303v1
糖尿病薬のリーグ戦、「優勝」した薬剤は？ | ドクターズアイ 山田悟（糖尿病） | Medical Tribune
（総合評価）：SGLT2阻害薬が第一選択薬
medical-tribune.co.jp/theme/doctor...
（総合評価）：SGLT2阻害薬が第一選択薬
medical-tribune.co.jp/theme/doctor...
糖尿病薬のリーグ戦、「優勝」した薬剤は？ | Medical Tribune
研究の背景：糖尿病治療薬の選択において臓器保護効果が注目されている
2006年に初版が発表された米国糖尿病学会（ADA）と欧州糖尿病学会（EASD）の薬物療法アルゴリズムにおいては、長らく糖尿病と診断すると同時にメトホルミンの投与が推奨され、メトホルミンは不動の第一選択薬であった（Diabetes Care 2006
medical-tribune.co.jp
November 16, 2024 at 2:03 AM
糖尿病薬のリーグ戦、「優勝」した薬剤は？ | ドクターズアイ 山田悟（糖尿病） | Medical Tribune
（総合評価）：SGLT2阻害薬が第一選択薬
medical-tribune.co.jp/theme/doctor...
（総合評価）：SGLT2阻害薬が第一選択薬
medical-tribune.co.jp/theme/doctor...
SGLT2阻害薬が2型糖尿病患者の全身性炎症を軽減 骨格筋内脂肪は糖尿病リスクを高める 米国内分泌学会(ENDO 2024)ダイジェスト(2) - 糖尿病リソースガイド
news.google.com/rss/articles/CBMiO2h0dHBzOi8vZG0tcmcubmV0L25ld3MvODkxMTE4YzQtZjRiYy00NmRhLWJkNjUtNzY4NDMzODM0ZmNh0gEA?oc=5
news.google.com/rss/articles/CBMiO2h0dHBzOi8vZG0tcmcubmV0L25ld3MvODkxMTE4YzQtZjRiYy00NmRhLWJkNjUtNzY4NDMzODM0ZmNh0gEA?oc=5
June 18, 2024 at 7:09 PM
SGLT2阻害薬が2型糖尿病患者の全身性炎症を軽減 骨格筋内脂肪は糖尿病リスクを高める 米国内分泌学会(ENDO 2024)ダイジェスト(2) - 糖尿病リソースガイド
news.google.com/rss/articles/CBMiO2h0dHBzOi8vZG0tcmcubmV0L25ld3MvODkxMTE4YzQtZjRiYy00NmRhLWJkNjUtNzY4NDMzODM0ZmNh0gEA?oc=5
news.google.com/rss/articles/CBMiO2h0dHBzOi8vZG0tcmcubmV0L25ld3MvODkxMTE4YzQtZjRiYy00NmRhLWJkNjUtNzY4NDMzODM0ZmNh0gEA?oc=5
https://gregory-ms.com/articles/286744/
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #NeuroSkyence
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #NeuroSkyence
August 26, 2024 at 7:50 AM
https://gregory-ms.com/articles/286744/
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #NeuroSkyence
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #NeuroSkyence
SGLT2 Inhibitor #SGLT2i in #Diabetic and #NonDiabetic Renal #Transplant Recipients
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
December 9, 2024 at 3:00 PM
SGLT2 Inhibitor #SGLT2i in #Diabetic and #NonDiabetic Renal #Transplant Recipients
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
#VisualAbstract by @DrPSVali
www.kireports.org/ar...
🩺💊 Yaygın diyabet ilacı kanser tedavisinde kalbi koruyabilir. Yeni bir araştırmaya göre, SGLT2 inhibitörü adı verilen diyabet ilacı, kanser tedavisi gören hastaların kalp sağlığını koruyarak daha iyi bir iyileşme sağlayabilir. 💖📉
March 6, 2025 at 5:31 PM
🩺💊 Yaygın diyabet ilacı kanser tedavisinde kalbi koruyabilir. Yeni bir araştırmaya göre, SGLT2 inhibitörü adı verilen diyabet ilacı, kanser tedavisi gören hastaların kalp sağlığını koruyarak daha iyi bir iyileşme sağlayabilir. 💖📉
A persistent eGFR drop with SGLT2 inhibitors is usually a functional change, not CKD, unless markers of kidney damage (e.g., albuminuria) are present. Document as a medication effect, not CKD, unless other evidence suggests true kidney disease. Reassure and monitor the patient are best next steps
December 27, 2024 at 12:25 PM
A persistent eGFR drop with SGLT2 inhibitors is usually a functional change, not CKD, unless markers of kidney damage (e.g., albuminuria) are present. Document as a medication effect, not CKD, unless other evidence suggests true kidney disease. Reassure and monitor the patient are best next steps
SGLT2 inhibitors may be option for Fabry-related proteinuria: Study - goo.gl/alerts/gYtCHx #GoogleAlerts
SGLT2 inhibitors may be option for Fabry-related proteinuria: Study
SGLT2 inhibitors, medications approved for diabetes, may be used in Fabry disease to reduce protein in the urine, according to a real-world study.
goo.gl
January 17, 2025 at 2:45 AM
SGLT2 inhibitors may be option for Fabry-related proteinuria: Study - goo.gl/alerts/gYtCHx #GoogleAlerts
多様で有益な効果は「全身の細胞の飢餓化」が影響か【時流◆SGLT2阻害薬の多様な臓器保護作用】 - m3.com
news.google.com/rss/articles/CBMiUEFVX3lxTE85NXZGSGZ4bHJ5akxfYXhlZVB0S2lGUW1NT3RxU25id3Z3QXhvTVJRY295bkVDQVBCLWgtQnpJa1pqdUxLa084QVRPUi1qd1pL?oc=5
news.google.com/rss/articles/CBMiUEFVX3lxTE85NXZGSGZ4bHJ5akxfYXhlZVB0S2lGUW1NT3RxU25id3Z3QXhvTVJRY295bkVDQVBCLWgtQnpJa1pqdUxLa084QVRPUi1qd1pL?oc=5
August 16, 2024 at 11:09 PM
多様で有益な効果は「全身の細胞の飢餓化」が影響か【時流◆SGLT2阻害薬の多様な臓器保護作用】 - m3.com
news.google.com/rss/articles/CBMiUEFVX3lxTE85NXZGSGZ4bHJ5akxfYXhlZVB0S2lGUW1NT3RxU25id3Z3QXhvTVJRY295bkVDQVBCLWgtQnpJa1pqdUxLa084QVRPUi1qd1pL?oc=5
news.google.com/rss/articles/CBMiUEFVX3lxTE85NXZGSGZ4bHJ5akxfYXhlZVB0S2lGUW1NT3RxU25id3Z3QXhvTVJRY295bkVDQVBCLWgtQnpJa1pqdUxLa084QVRPUi1qd1pL?oc=5
Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan
Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays
the progression of chronic kidney disease (CKD), its effect on patients with autosomal
dominant polycystic kidney dis...
www.kireports.org
March 26, 2025 at 5:42 PM
Our topic:
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
Use of dapagliflozin (SGLT2 inhibitor) in patients with autosomal dominant polycystic kidney disease (ADPKD) concurrently on tolvaptan therapy. There are no conflicts of interest.
#MedSky #NephSky
Article: www.kireports.org/article/S2468-0249(25)00048-8/fulltext
【SGLT2-iで２型DM例の冠動脈炎症抑制？/ Cardiovasc
Diabetol】
中国単施設、CCTA施行２型DM 271例解析：
・SGLT2-i「服用」例では「非服用」に比べ、炎症指標である
冠動脈周囲FAIが、LAD/RCAで有意に低値。
・LCXでは有意差認めず。
x.gd/zN3qp
Diabetol】
中国単施設、CCTA施行２型DM 271例解析：
・SGLT2-i「服用」例では「非服用」に比べ、炎症指標である
冠動脈周囲FAIが、LAD/RCAで有意に低値。
・LCXでは有意差認めず。
x.gd/zN3qp
Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index - Cardiovascular Diabetology
Background The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become an important component of standard tr...
x.gd
April 21, 2025 at 12:26 AM
【SGLT2-iで２型DM例の冠動脈炎症抑制？/ Cardiovasc
Diabetol】
中国単施設、CCTA施行２型DM 271例解析：
・SGLT2-i「服用」例では「非服用」に比べ、炎症指標である
冠動脈周囲FAIが、LAD/RCAで有意に低値。
・LCXでは有意差認めず。
x.gd/zN3qp
Diabetol】
中国単施設、CCTA施行２型DM 271例解析：
・SGLT2-i「服用」例では「非服用」に比べ、炎症指標である
冠動脈周囲FAIが、LAD/RCAで有意に低値。
・LCXでは有意差認めず。
x.gd/zN3qp